All In Biotech

Drug Trial Radar · NCT07028801

Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)

A Randomized, Blinded, Parallel Controlled, Non-inferiority Design Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) Administered to Participants Aged 10 to 60 Years With Different Immunization Schedules

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,000

Actual

Start

Jul 30, 2025

Primary completion

Apr 8, 2026

Study completion Apr 10, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 10 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Phase 3 clinical trial of freeze-dried human rabies vaccine (human diploid cells) adopted a randomized, blinded, parallel control,non-inferiority design,and administered vaccines to participants aged 10 to 60 years with different immunization schedules (5-dose schedule group, two simple 4-dose schedule groups, and 2-1-1 schedule group) to evaluate the immunogenicity and safety of the vaccine.

Conditions

  • Rabies

Interventions

  • Freeze-dried human rabies vaccine (human diploid cells)Biological

    This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 1 dose on day 0, 3, 7, 14 and 28, total 5 doses

  • Freeze-dried human rabies vaccine (human diploid cells)Biological

    This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 1 dose on day 0, 3, 7 and 14, total 4 doses

  • Freeze-dried human rabies vaccine (human diploid cells)Biological

    This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 1 dose on day 0, 3, 7 and 28, total 4 doses

  • Freeze-dried human rabies vaccine (human diploid cells)Biological

    This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection. Receive 2 dose on day 0, 1 dose on day 7 and 21, total 4 doses

  • Freeze-dried human rabies vaccine (human diploid cells)Biological

    This vaccine is produced by Chengdu Kanghua Biological Products Co., LTD Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection Receive 1 dose on day 0, 3, 7, 14and 28, total 5 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Antibody SCR for the 5-dose schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
  2. Antibody GMC for the 5-dose schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
  3. Antibody SCR for the simple 4-dose schedule group 1 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
  4. Antibody GMC for the simple 4-dose schedule group 1 of the trial vaccine and the 5-dose schedule of the control vaccineTime frame: 14 days after the first dose
  5. Antibody SCR for the simple 4-dose schedule group 2 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
  6. Antibody GMC for the simple 4-dose schedule group 2 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
  7. Antibody SCR for the 2-1-1 schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
  8. Antibody GMC for the 2-1-1 schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after the first dose
  9. Antibody SCR for the 5-dose schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination
  10. Antibody SCR for the simple 4-dose schedule group 1 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination
  11. Antibody SCR for the simple 4-dose schedule group 2 of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination
  12. Antibody SCR for the 2-1-1 schedule group of the trial vaccine and the 5-dose schedule group of the control vaccineTime frame: 14 days after full vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Provincial Center for Disease Control and Prevention

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.